Peptides

Details Peptides Peptides

2007-03-20

2007-03-20

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S324000, C530S326000, C424S278100

Reexamination Certificate

active

10776224

ABSTRACT:
Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.

REFERENCES:
patent: 5856171 (1999-01-01), Korsmeyer
patent: WO 92/14756 (1992-09-01), None
patent: WO 95/32731 (1995-12-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 97/12992 (1997-04-01), None
patent: WO 99/10382 (1999-03-01), None
patent: WO 99/58564 (1999-11-01), None
Rampino et al. (1997), Science 275:967-969, “Somatic Frameshift Mutations in the BAX Gen in Colon Cancers of the Microsatellite Mutator Pheotype”.
Yamamoto et al. (Mar. 1998), Cancer Research 58:997-1003, “Somatic Frameshift Mutations in DNA Mismatch Repair and Proapoptosis Genes in Hereditary Nonpolyposis Colorectal Cancer”.
Markowitz et al. (1995), Science 268:1336-1338, “Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability”.
Gaudernack (1996), Immunotechnology 2:3-9, “T cell responses against mutantras: a basis for novel cancer vaccines”.
Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, “Ex Vivoras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study”.
Gjertsen et al. (1996), British Journal of Cancer 74:1828-1833, “Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination”.
Gjertsen et al. (1997), Int. J. Cancer 72:784-790, “Cytotoxic CD4+and CD8+T-Lymphocyt s, Generated by Mutant p21-ras(12Val) Peptide Vaccination of a Patient, Recognize . . . Tumour Cells Carrying This Mutation”.
Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, “Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer”.
Barinaga, (1992) Science, vol. 257, pp. 880-881, “Getting Some Backbone: How MHC Binds Peptides”.
Deres et al., (1989) Nature, vol. 342, pp. 561-564, “In vivopriming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine”.
Tighe et al., (1998) Immun. Today, vol. 19(2), pp. 89-97, “Gene vaccination: plasmid DNA is more than just a blueprint”.

Affiliated with

Also associated with

Rating

Peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3798057